Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Expedition Growth Capital in connection with investment in Xensam
Mandate

Vinge advises Expedition Growth Capital in connection with investment in Xensam  

February 09, 2024 Employment and Benefits Intellectual Property M&A

Expedition Growth Capital has today announced a $40 million growth investment in the Swedish SaaS company Xensam. Vinge acted as Expedition Growth Capital’s legal advisor in connection with the investment.

Xensam is a provider of an AI-powered Software Assessment Management (SAM) platform. The platform enables its customers to understand how users interact with applications, whether SaaS or on-premise, across the entire digital infrastructure to provide a comprehensive organisational overview across hybrid environments.

Expedition Growth Capital is a London-based growth fund focused on investing in fast-growing companies.

Vinge’s team consisted of Karl Klackenberg, Clara Sohlberg and Johan Gavelin (M&A), Rebecka Målquist (IP), Olivia Onwuta (Employment) and Anna Ekdahl Roos (Transaction Support).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025